dtx

By Dave Muoio 04:53 pm September 11, 2020
International pharma Boehringer Ingelheim and prescription digital therapeutics company Click Therapeutics have inked a $500 million-plus deal to jointly develop and commercialize a digital treatment for patients with schizophrenia. The treatment, referred to as CT-155, will be a mobile app built on Click's proprietary tech platform, the companies said. Employing cognitive and neurobehavioral...
By Dave Muoio 01:40 pm August 31, 2020
Pear Therapeutics highlighted data today from two studies of a digital cognitive behavioral therapy that acted as the precursor for Somryst, the prescription digital therapeutic for adults with chronic insomnia that was the first to pass through the FDA's Pre-Cert pilot pathway. The first, a randomized controlled trial of 1,149 Australian adults with insomnia and depressive symptoms, suggested...
By Aline Noizet 02:16 am April 29, 2020
Dr. Morcillo is the director of internal medicine Hospital Cima Sanitas in Barcelona and the medical director of Sanitas digital hospital. He is an active advocate and user of digital technologies in his daily practice. He will join the HIMSS & Health 2.0 European Digital Event (7-11 September 2020) as an expert in the session on digital therapeutics. The below Q&A has been edited for...
By Dave Muoio 06:00 am April 22, 2020
Less than a week after FDA opened the faucet for digital health products treating psychiatric conditions during the COVID-19 health crisis, Akili has fast-tracked and released its approval-pending digital therapeutic for children with ADHD. Now known as Endeavor and flanked by a symptom tracker and caretaker support line, the video game-like app will be provided at no cost for a limited time to...
By Dave Muoio 04:28 pm April 8, 2020
Easy access to (temporarily) free counseling. Consumer telehealth and mail-order prescription services Hims and Hers are dipping into the mental health wellness space. The brands kicked off new anonymized group therapy and guided meditation offerings yesterday, with the therapy sessions led by a licensed mental health practitioner. The group sessions are currently being offered free of charge in...
By Dave Muoio 03:53 pm March 26, 2020
Pear Therapeutics announced this morning that Somryst, its prescription digital therapeutic for adults with chronic insomnia, has received marketing authorization from the FDA. The treatment provides cognitive behavioral therapy for insomnia (CBTi) alongside personalized, algorithm-generated sleep restriction recommendations. The digital therapeutic was reviewed through the agency's 510(k)...
By Dave Muoio 04:05 pm January 7, 2020
Editor's note: This story has been updated with additional statements from Pear Therapeutics. Pear Therapeutics pulled back the curtain this morning on a number of new deals between the prescription digital therapeutics maker and other tech companies or researchers. Ranging from virtual reality therapies to voice biomarker tech, the moves appear to be an effort from Pear to add new products to...
By Laura Lovett 03:48 pm December 12, 2019
A video game-like digital therapy may be key to helping reduce cognitive impairments in adults living with major depressive disorder (MDD).  Results out of a new study conducted by Akili interactive found that patients using the company’s AKL-T03 significantly improved their sustained attention compared to their peers in the control group.  In the study, which was presented at the Meeting of the...
By Dave Muoio 11:47 am October 30, 2019
Pear Therapeutics has announced a new deal with Ironwood Pharmaceuticals that will explore the platform’s potential for patients with certain gastrointestinal (GI) conditions. “We are excited to be partnering with Ironwood on this initiative and believe there is a compelling clinical rationale for use of [prescription digital therapeutics] in treating GI diseases,” Dr. Corey McCann, president and...
By Dave Muoio 10:28 am October 16, 2019
Editor's Note: This story has been updated with additional quotes from Pear Therapeutics. The poster child of digital therapeutics-pharma collaborations is soon to be no more, as Novartis division Sandoz announced that it is handing sole responsibility for the commercialization of the reSET and reSET-O prescription digital therapeutics back to Pear Therapeutics. “Pear and Sandoz previously signed...